ADVAGENE BIOPHARMA CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.advagene.com.tw
Clinical Trials
6
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
2 (33.3%)Not Applicable
1 (16.7%)AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Advagene Biopharma Co. Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05985694
- Locations
- 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan, Taiwan
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Biological: PlaceboBiological: AD17002 + Formulation buffer
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Advagene Biopharma Co. Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05541510
- Locations
- 🇮🇩
RSPI Sulianti Saroso, Kota Jkt Utara, DKI Jakarta, Indonesia
🇮🇩RSDC Wisma Atlit, Kota Jkt Utara, DKI Jakarta, Indonesia
🇮🇩RSA UGM, Yogyakarta, Special Region of Yogyakarta, Indonesia
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Advagene Biopharma Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05069610
- Locations
- 🇨🇳
Advagene Biopharma, Taipei, Taiwan
🇨🇳Chang Gun Medical Foundation, Taoyuan, Taiwan
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
Phase 1
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Other: Formulation Buffer
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Advagene Biopharma Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04088721
- Locations
- 🇨🇳
Taipei Medical University, Taipei, Taiwan, Taiwan
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
Phase 2
Completed
- Conditions
- Influenza Infection
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Advagene Biopharma Co. Ltd.
- Target Recruit Count
- 345
- Registration Number
- NCT03784885
- Locations
- 🇨🇳
Advagene Biopharma, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
No news found